Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Myeloma Heterogeneity within Its Complex Immune Ecosystem

Jana Jakubikova, PhD, Danka Cholujova, PhD, Gabor Beke, PhD, Zachary R Hunter, PhD, Teru Hideshima, MD PhD, Merav Leiba, MD, Krzysztof Jamroziak, MD PhD, Paul G. Richardson, MD, Eftathios Kastritis, David M. Dorfman, MD PhD, Kenneth C. Anderson, MD

Blood (2019) 134 (Supplement_1): 4354.

https://doi.org/10.1182/blood-2019-132193

Published: 2019

Journal Articles

High-Dimensional Heterogeneity of Waldenström Macroglobulinemia within Its Immune Tumor Microenvironment

Jana Jakubikova, PhD, Danka Cholujova, PhD, Gabor Beke, PhD, Zachary R Hunter, PhD, Teru Hideshima, MD PhD, Ludmila Flores, Merav Leiba, MD, Paul G. Richardson, MD, Eftathios Kastritis, David M. Dorfman, MD PhD, Steven P Treon, MD PhD FRCP, Kenneth C. Anderson, MD

Blood (2019) 134 (Supplement_1): 3975.

https://doi.org/10.1182/blood-2019-130011

Published: 2019

Journal Articles

STK405759 As a Novel Tubulin Active Agent for Multiple Myeloma Therapy

Gabriela Rozic, PhD, Paukov Lena, MSc, Jana Jakubikova, PhD, Duek Adrian, MD, Abraham Avigdor, MD, Arnon Nagler, MD MSc, Merav Leiba, MD

Blood (2015) 126 (23): 5348.

https://doi.org/10.1182/blood.V126.23.5348.5348

Published: 2015

Journal Articles

Inter and Intra-Clonal Heterogeneity in Multiple Myeloma and Waldenstrom Macroglobulinemia

Jana Jakubikova, PhD, Danka Cholujova, PhD, Teru Hideshima, MD PhD, Jacob P. Laubach, MD, Nikhil C. Munshi, MD, Steven P. Treon, MD PhD, Paul Richardson, MD, Efstathios Kastritis, MD, David M Dorfman, MD PhD, Kenneth C. Anderson, MD PhD

Blood (2014) 124 (21): 2070.

https://doi.org/10.1182/blood.V124.21.2070.2070

Published: 2014

Journal Articles

Evaluation of Immune Profile in Patients with Multiple Myeloma Using Cytof Technology

Jana Jakubikova, PhD, Efstathios Kastritis, MD, Danka Cholujova, PhD, Teru Hideshima, MD PhD, Ludmila M Flores, Merav Leiba, MD, Jacob P. Laubach, MD, Nikhil C. Munshi, MD, Paul Richardson, MD, David M Dorfman, MD PhD, Kenneth C. Anderson, MD PhD

Blood (2014) 124 (21): 3404.

https://doi.org/10.1182/blood.V124.21.3404.3404

Published: 2014

Journal Articles

Mimicking Myeloma Niche Ex Vivo

Jana Jakubikova, PhD, Danka Cholujova, PhD, Richard W Groen, PhD, Jungnam Joo, PhD, Sun-Young Kong, MD PhD, Teru Hideshima, MD PhD, Rikio Suzuki, MDPhD, Jan Sedlak, PhD, Constantine S Mitsiades, MD PhD, David M Dorfman, MD PhD, Jacob P. Laubach, MD, Nikhil C. Munshi, MD, Paul G. Richardson, MD PhD, Kenneth Anderson, MD PhD

Blood (2014) 124 (21): 2076.

https://doi.org/10.1182/blood.V124.21.2076.2076

Published: 2014

Journal Articles

Cell Non-Autonomous Modulation Of Tumor Cell Responses To Pharmacological Inhibition Of The Proteasome

Eugen Dhimolea, PhD, Richard W.J. Groen, PhD, Catriona A. Hayes, MD, Jana Jakubikova, PhD, Bariteau Megan, Jake E. Delmore, Hannah M. Jacobs, Julio-Cesar Marin, Gregory Della Penna, Douglas W. McMillin, PhD, Ana Acuna, Panisinee Lawasut, MD, Nancy Kohl, PhD, Constantine S. Mitsiades, MD, PhD

Blood (2013) 122 (21): 4454.

https://doi.org/10.1182/blood.V122.21.4454.4454

Published: 2013

Journal Articles

Nanoparticle Arsenic Compound Realgar Effectively Targets Myeloma Stem-Like Side Population

Jana Jakubikova, PhD, Teru Hideshima, MD, PhD, Richard W.J. Groen, PhD, Danka Cholujova, PhD, Zdenka Bujnakova, PhD, Jacob P. Laubach, MD, Nikhil C. Munshi, MD, Paul G. Richardson, MD, Constantine S. Mitsiades, MD, PhD, Peter Balaz, PhD, Jan Sedlak, PhD, Kenneth C. Anderson, MD

Blood (2013) 122 (21): 4455.

https://doi.org/10.1182/blood.V122.21.4455.4455

Published: 2013

Journal Articles

Myeloma Patient-Derived Mesenchymal Stem Cells Grown In 3-D Culture Induce Primary Myeloma Cell Proliferation and Resistance To Therapy

Jana Jakubikova, PhD, Richard W.J. Groen, PhD, Teru Hideshima, MD, PhD, Danka Cholujova, PhD, Jan Sedlak, PhD, Constantine S. Mitsiades, MD, PhD, Jacob P. Laubach, MD, Nikhil C. Munshi, MD, Paul G. Richardson, MD, Kenneth C. Anderson, MD

Blood (2013) 122 (21): 1912.

https://doi.org/10.1182/blood.V122.21.1912.1912

Published: 2013

Journal Articles

Co-Expression Of The MUC1 Oncoprotein and CD34 On Primary Myeloma Bone Marrow Cells Identifies a Population With Myeloma Initiating Potential

Blood (2013) 122 (21): 127.

https://doi.org/10.1182/blood.V122.21.127.127

Published: 2013

Journal Articles

Formation of the Functional Niche in Vitro by Mimicking the Pathophysiological Features of the Bone Marrow Microenvironment in Multiple Myeloma

Jana Jakubikova, PhD, Richard W.J. Groen, PhD, Sophia Adamia, PhD, Teru Hideshima, MD, PhD, Danka Cholujova, PhD, Jacob P. Laubach, MD, Nikhil C. Munshi, MD, Paul G. Richardson, MD, Kenneth C. Anderson, MD

Blood (2012) 120 (21): 1812.

https://doi.org/10.1182/blood.V120.21.1812.1812

Published: 2012

Journal Articles

Tumor Cell-Dependent Differences in Stroma-Induced Changes to Bortezomib Sensitivity.

Eugen Dhimolea, PhD, Jana Jakubikova, PhD, Richard W.J. Groen, PhD, Jake E. Delmore, Hannah M. Jacobs, Douglas W. McMilllin, Ana Acuña-Villaorduña, MD, Catriona A. Hayes, MD, Panisinee Lawasut, MD, Constantine S. Mitsiades, MD, PhD

Blood (2012) 120 (21): 2468.

https://doi.org/10.1182/blood.V120.21.2468.2468

Published: 2012

Journal Articles

Proteomic Characterization of An Isogenic Multiple Myeloma Cell Line Model of Bortezomib Resistance

*Catriona A. Hayes, MD, *Paul Dowling, PhD, Joseph Negri, Michael Henry, Leutz Buon, Jana Jakubikova, PhD, Jake E Delmore, Douglas W. McMillin, PhD, Steffen Klippel, PhD, Hannah M. Jacobs, Niels W.C.J. van de Donk, MD, PhD, Eugen Dhimolea, PhD, Panisinee Lawasut, MD, MSc, Paul G. Richardson, MD, Kenneth C. Anderson, MD, Martin Clynes, PhD, *Peter O Gorman, MD, PhD, *Constantine S. Mitsiades, MD, PhD

Blood (2011) 118 (21): 1820.

https://doi.org/10.1182/blood.V118.21.1820.1820

Published: 2011

Journal Articles

Proteasome Inhibitors Sensitize Myeloma Cells to T Cell-Mediated Killing

Niels W.C.J. van de Donk, MD, PhD, Henk M. Lokhorst, MD, Maarten Emmelot, Tineke Aarts-Riemens, Douglas W. McMillin, PhD, Gullu Gorgun, PhD, Steffen Klippel, PhD, Eugen Dhimolea, PhD, Jana Jakubikova, PhD, Catriona A. Hayes, MD, Panisinee Lawasut, MD, Jake E Delmore, Nikhil C. Munshi, MD, Paul G. Richardson, MD, Kenneth C. Anderson, MD, Constantine S. Mitsiades, MD, PhD, Tuna Mutis, MD PhD

Blood (2011) 118 (21): 1838.

https://doi.org/10.1182/blood.V118.21.1838.1838

Published: 2011

Journal Articles

Blockade of Nuclear Export Protein CRM1 (chromosomal region maintenance 1, XPO1) by a Novel, Potent and Selective CRM1 Inhibitor KPT-185 Induces Significant Antitumor Activity Against Human Multiple Myeloma

Sun-Young Kong, MD, PhD, Yosef Landesman, PhD, Jana Jakubikova, PhD, Michael A. Sellitto, Antonia Cagnetta, MD, Michele Cea, MD, Michelle C. Chen, Francesca Cottini, MD, Douglas W. McMillin, PhD, Chirag Acharya, MD, William Senapedis, PhD, Sharon Shacham, PhD, MBA, Michael Kauffman, MD, PhD, Dilara McCauley, PhD, Jean-Richard Saint-Martin, BS, Nikhil C. Munshi, MD, Paul G. Richardson, MD, Kenneth C. Anderson, MD, Yu-Tzu Tai, PhD

Blood (2011) 118 (21): 2913.

https://doi.org/10.1182/blood.V118.21.2913.2913

Published: 2011

Journal Articles

Targeting NAD + Salvage Pathway Induces Autophagy in Multiple Myeloma Cells

Michele Cea, MD, Antonia Cagnetta, MD, Yu-Tzu Tai, PhD, Mariateresa Fulciniti, PhD, Teru Hideshima, MD, PhD, Dharminder Chauhan, PhD, Sun-Young Kong, MD, PhD, Teresa Calimeri, M.D., Francesca Cottini, MD, Jana Jakubikova, PhD, Alessio Nencioni, Marco Gobbi, MD, Franco Patrone, Kenneth C. Anderson, MD

Blood (2011) 118 (21): 2920.

https://doi.org/10.1182/blood.V118.21.2920.2920

Published: 2011

Journal Articles

Synergistic Enhancement of Conventional Anti-MM Drugs Efficacy with Plant Isothiocyanates: Therapeutic Implications

Jana Jakubikova, PhD, Melissa Ooi, MD, Steffen Klippel, PhD, Jake Delmore, Jacob P. Laubach, MD, Paul G Richardson, MD, Jan Sedlak, PhD, Kenneth C. Anderson, MD, Constantine S. Mitsiades, MD, PhD

Blood (2010) 116 (21): 5016.

https://doi.org/10.1182/blood.V116.21.5016.5016

Published: 2010

Journal Articles

Development of New Treatment Strategies Targeting Clonogenic and Tumorigenic Myeloma Side Population.

Jana Jakubikova, PhD, Steffen Klippel, PhD, Efstathios Kastritis, MD, John Daley, Melissa Ooi, MD, Jake Delmore, Jacob P. Laubach, MD, Paul G Richardson, MD, Jan Sedlak, PhD, Kenneth C. Anderson, MD, Constantine S. Mitsiades, MD, PhD

Blood (2010) 116 (21): 1581.

https://doi.org/10.1182/blood.V116.21.1581.1581

Published: 2010

Journal Articles

Halofuginone, an Old Anticoccidosis Drug, Induces Apoptosisin Multiple Myeloma Cells, Associated with Down Regulation of MCL1.

Merav Leiba, MD, Yu-Tzu Tai, PHD, Teru Hideshima, MD, PHD, Jana Jakubikova, PHD, Ikeda Hiroshi, MD, PHD, Xian-Feng Li, MS, Peter Burger, BS, Paul Richardson, MD, Nikhil C. Munshi, MD, Arnon Nagler, MD, Kenneth C. Anderson, MD

Blood (2007) 110 (11): 4786.

https://doi.org/10.1182/blood.V110.11.4786.4786

Published: 2007

NARROW

Myeloma Heterogeneity within Its Complex Immune Ecosystem

High-Dimensional Heterogeneity of Waldenström Macroglobulinemia within Its Immune Tumor Microenvironment

STK405759 As a Novel Tubulin Active Agent for Multiple Myeloma Therapy

Inter and Intra-Clonal Heterogeneity in Multiple Myeloma and Waldenstrom Macroglobulinemia

Evaluation of Immune Profile in Patients with Multiple Myeloma Using Cytof Technology

Mimicking Myeloma Niche Ex Vivo

Cell Non-Autonomous Modulation Of Tumor Cell Responses To Pharmacological Inhibition Of The Proteasome

Nanoparticle Arsenic Compound Realgar Effectively Targets Myeloma Stem-Like Side Population

Myeloma Patient-Derived Mesenchymal Stem Cells Grown In 3-D Culture Induce Primary Myeloma Cell Proliferation and Resistance To Therapy

Co-Expression Of The MUC1 Oncoprotein and CD34 On Primary Myeloma Bone Marrow Cells Identifies a Population With Myeloma Initiating Potential

Formation of the Functional Niche in Vitro by Mimicking the Pathophysiological Features of the Bone Marrow Microenvironment in Multiple Myeloma

Tumor Cell-Dependent Differences in Stroma-Induced Changes to Bortezomib Sensitivity.

Proteomic Characterization of An Isogenic Multiple Myeloma Cell Line Model of Bortezomib Resistance

Proteasome Inhibitors Sensitize Myeloma Cells to T Cell-Mediated Killing

Blockade of Nuclear Export Protein CRM1 (chromosomal region maintenance 1, XPO1) by a Novel, Potent and Selective CRM1 Inhibitor KPT-185 Induces Significant Antitumor Activity Against Human Multiple Myeloma

Targeting NAD + Salvage Pathway Induces Autophagy in Multiple Myeloma Cells

Synergistic Enhancement of Conventional Anti-MM Drugs Efficacy with Plant Isothiocyanates: Therapeutic Implications

Development of New Treatment Strategies Targeting Clonogenic and Tumorigenic Myeloma Side Population.

Halofuginone, an Old Anticoccidosis Drug, Induces Apoptosisin Multiple Myeloma Cells, Associated with Down Regulation of MCL1.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only